Phase 2 Clinical Trial Progress Update
CRISM Therapeutics Corporation has provided an update on its Phase 2 clinical trial for irinotecan-ChemoSeed in glioblastoma, announcing that its contract manufacturer has successfully produced the first clinical batch of ChemoSeed. While the batch is undergoing final testing, the company is working with its contract research organisation and trial site to complete activation steps for patient dosing. Due to the ongoing site activation process, CRISM Therapeutics is extending its guidance for first patient dosing to the first half of 2026, and will provide further updates on trial commencement as soon as possible.
Select text to share a quote on X · sign in to keep highlights & notes in your CRTX notes
596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018.
CRISM Therapeutics Corporation
("CRISM", "CRISM Therapeutics" or the "Company")
Phase 2 Clinical Trial Progress Update
CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, provides a progress update on its Phase 2 clinical trial of irinotecan-ChemoSeed in glioblastoma.
The Company confirms that its US-based contract development and manufacturing organisation, ProMed Pharma LLC, has successfully manufactured the first clinical batch of ChemoSeed in accordance with current Good Manufacturing Practice standards. The batch will now undergo sterilisation and release testing, making it ready for use in the Phase 2 trial.
The Company also continues to work closely with its contract research organisation, Aixial, and the first clinical trial site, to complete the remaining site activation steps so as to commence patient dosing. Although progress toward trial commencement is moving at pace, the exact timing of first patient dosing is difficult to anticipate. As such, the Company is extending guidance on the timing of first patient dosing to H1 2026. The Company remains focused on initiating the trial shortly and will provide further updates on the commencement of the trial as soon as possible.
The Company's LEI is 213800XFW6MKVCHHPW88.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.